1620874-85-2

Upstream product

• 1620874-84-1 5-hydroxy-4-(4-methylbenzoylamino)-2-nitrobenzoic acid ethyl ester 
• 1620874-83-0 4-amino-5-hydroxy-2-nitrobenzoic acid ethyl ester 
• 1620874-92-1 4-amino-5-hydroxy-2-nitrobenzoic acid hydrochloride 
• 600713-80-2 5-methoxy-2-nitro-4-(2,2,2-trifluoroacetamido)benzoic acid 
• 2486-69-3 3-methoxy-4-aminobenzoic acid 
• 212118-11-1 3-methoxy-4-(2,2,2-trifluoroacetamido)benzoic acid 

Downstream Products

• 1620874-86-3 7-chloro-5-nitro-2-(p-tolyl)benzoxazole-6-carboxylic acid ethyl ester 
• 1620874-87-4 5-amino-7-chloro-2-(p-tolyl)benzoxazole-6-carboxylic acid ethyl ester 
• 1620874-75-0 2-(5-amino-7-chloro-2-(p-tolyl)benzoxazol-6-yl)propan-2-ol 

Relevant academic research and scientific papers

ALDEHYDE CONJUGATES AND USES THEREOF

The present invention provides compounds and methods of use thereof for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

NOVEL TRAPS IN THE TREATMENT OF MACULAR DEGENERATION

The present invention is directed to compounds of formula (A): pharmaceutical compositions, and methods of use for treating, reducing a symptom of or reducing the risk of macular degeneration.